Abstract
As one of the leading causes of deaths worldwide, cancer is posing threat despite efforts being taken to develop effective anticancer drugs. There is an increase in number of chemotherapy treatments due to growing number of manifestations causing increasing toxicities of cytotoxic agents. Almost all the anticancer agents available till date have one or the other side effects. Topoisomerases are the attractive targets to develop effective anticancer agents. There has been development of many topoisomerase inhibitors till date and has shown good anticancer activity but their side effects outnumber their anticancer potential. Hence, there is an urgent need to develop effective therapeutic agents with fewer side effects. This review deals with design and development aspect of topoisomerase inhibitors as exciting novel anticancer agents. The emphasis has been laid in particular on the new potential heterocyles as TOP inhibitors in the field of medicinal chemistry. The review discusses about the topoisomerase poisons, TOP1 suppressors, TOP inhibitors and Dual TOP 1/2 inhibitors.
Keywords: Anticancer, topoisomerase types and inhibitors, structure activity relationship, topoisomerase inhibitors.
Mini-Reviews in Medicinal Chemistry
Title:Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Volume: 16 Issue: 15
Author(s): Muthu K. Kathiravan, Anuj N. Kale and Shrikant Nilewar
Affiliation:
Keywords: Anticancer, topoisomerase types and inhibitors, structure activity relationship, topoisomerase inhibitors.
Abstract: As one of the leading causes of deaths worldwide, cancer is posing threat despite efforts being taken to develop effective anticancer drugs. There is an increase in number of chemotherapy treatments due to growing number of manifestations causing increasing toxicities of cytotoxic agents. Almost all the anticancer agents available till date have one or the other side effects. Topoisomerases are the attractive targets to develop effective anticancer agents. There has been development of many topoisomerase inhibitors till date and has shown good anticancer activity but their side effects outnumber their anticancer potential. Hence, there is an urgent need to develop effective therapeutic agents with fewer side effects. This review deals with design and development aspect of topoisomerase inhibitors as exciting novel anticancer agents. The emphasis has been laid in particular on the new potential heterocyles as TOP inhibitors in the field of medicinal chemistry. The review discusses about the topoisomerase poisons, TOP1 suppressors, TOP inhibitors and Dual TOP 1/2 inhibitors.
Export Options
About this article
Cite this article as:
Kathiravan K. Muthu, Kale N. Anuj and Nilewar Shrikant, Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents, Mini-Reviews in Medicinal Chemistry 2016; 16 (15) . https://dx.doi.org/10.2174/1389557516666160822110819
DOI https://dx.doi.org/10.2174/1389557516666160822110819 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Tissue Engineering for Post-Myocardial Infarction Ventricular Remodeling
Mini-Reviews in Medicinal Chemistry The Future of Induced Pluripotent Stem Cells for Cardiac Therapy and Drug Development
Current Pharmaceutical Design Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Endothelin Signalling in the Cardiac Myocyte and its Pathophysiological Relevance
Current Vascular Pharmacology The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Mechanisms of the Beneficial Actions of Ischemic Preconditioning on Subcellular Remodeling in Ischemic-Reperfused Heart
Current Cardiology Reviews Treating Cancer in Older and Oldest Old Patients
Current Pharmaceutical Design Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Mitochondrial Trifunctional Protein Defects: Molecular Basis and Novel Therapeutic Approaches
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Current Status in Iron Chelation in Hemoglobinopathies
Current Molecular Medicine The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Clinical Application of Ghrelin
Current Pharmaceutical Design Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Using Extracellular Matrix-Derived Peptides to Alter the Microenvironment for Myocardial Repair
Current Vascular Pharmacology Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology